Back to search

Peptide record

TPDB06978

Tritrpticin Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity standard
13 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB06978
Tritrpticin
Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF Antifungipept CAFPdb APD_complete APD_hemolytic HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 13-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
VRRFPWWWPFLRR
Physicochemical Analysis
C96H132N28O14
ANDCEQGHIKMSTY
R
1902.28
12.88
4
0
7
+4
-4.16
-0.792
52.31
Mammalian: 100 hour Yeast: >20 hour E.coli: >10 hour
16500
867.38
0
Residue Composition
number
0
A
4
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
1
L
0
K
0
M
2
F
2
P
0
S
0
T
3
W
0
Y
1
V
Amino Acid Distribution
A: 0 R: 4 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 1 K: 0 M: 0 F: 2 P: 2 S: 0 T: 0 W: 3 Y: 0 V: 1
Chemical Descriptors
13
C96H132N28O14
1902.28
12.88
+4
-4.16
-0.792
Free
L
Linear
Free
Antimicrobial
Evidence Records 35 records
Evidence 1 Activity

Activity

MIC
Antibacterial
250 µg/mL

Target

A.fumigatus

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
aeruginosa, K. pneumonia, S. epidermidis, P. mirabilis, and Streptococcus group D, fungi A.fumigatus (MIC 250 ug/ml) and C.albicans (MIC 1000 ug/ml). Bacteriocidal. Also active against E. coli KCTC 1682 (MI
Evidence 2 Activity

Activity

MIC
Antibacterial
1000 µg/mL

Target

C.albicans

Source & Reference

dbAMP DRAMP

Other

idermidis, P. mirabilis, and Streptococcus group D, fungi A.fumigatus (MIC 250 ug/ml) and C.albicans (MIC 1000 ug/ml). Bacteriocidal. Also active against E. coli KCTC 1682 (MIC 32 ug/ml), S. typhimurium KCTC
Evidence 3 Activity

Activity

MIC
Antibacterial
32 µg/mL

Target

Escherichia coli KCTC 1682

Source & Reference

dbAMP DRAMP

Other

gatus (MIC 250 ug/ml) and C.albicans (MIC 1000 ug/ml). Bacteriocidal. Also active against E. coli KCTC 1682 (MIC 32 ug/ml), S. typhimurium KCTC 1926 (MIC 32 ug/ml), B. subtilis KCTC 3068 (MIC 8 ug/ml), and S. aur
Evidence 4 Activity

Activity

MIC
Antibacterial
32 µg/mL

Target

S. typhimurium KCTC 1926

Source & Reference

dbAMP DRAMP

Other

ns (MIC 1000 ug/ml). Bacteriocidal. Also active against E. coli KCTC 1682 (MIC 32 ug/ml), S. typhimurium KCTC 1926 (MIC 32 ug/ml), B. subtilis KCTC 3068 (MIC 8 ug/ml), and S. aureus KCTC 1621 or 2 strains MRSA (MIC 16-6
Evidence 5 Activity

Activity

MIC
Antibacterial
8 µg/mL

Target

B. subtilis KCTC 3068

Source & Reference

dbAMP DRAMP

Other

active against E. coli KCTC 1682 (MIC 32 ug/ml), S. typhimurium KCTC 1926 (MIC 32 ug/ml), B. subtilis KCTC 3068 (MIC 8 ug/ml), and S. aureus KCTC 1621 or 2 strains MRSA (MIC 16-64 ug/ml), 2 strains vancomycin-resist
Evidence 6 Activity

Activity

MIC
Antibacterial
16-64 µg/mL

Target

Staphylococcus aureus KCTC 1621 or MRSA

Source & Reference

dbAMP DRAMP

Other

ug/ml), S. typhimurium KCTC 1926 (MIC 32 ug/ml), B. subtilis KCTC 3068 (MIC 8 ug/ml), and S. aureus KCTC 1621 or 2 strains MRSA (MIC 16-64 ug/ml), 2 strains vancomycin-resistant E. faecium (MIC 32 ug/ml) anti-VRE. Nonstandard assays in
Evidence 7 Activity

Activity

MIC
Antibacterial
32 µg/mL

Target

E. faecium

Source & Reference

dbAMP DRAMP

Other

d S. aureus KCTC 1621 or 2 strains MRSA (MIC 16-64 ug/ml), 2 strains vancomycin-resistant E. faecium (MIC 32 ug/ml) anti-VRE. Nonstandard assays in 50% LB ( Yang et al., 2006 .
Evidence 8 Activity

Activity

IC50
IC50 = 18.3 µM
Anticancer
18.3 µM

Target

Blood Cancer
Jurkat
Blood

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2020

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 9 Activity

Activity

MIC
Antifungal
250 µg/mL

Target

A.fumigatus

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
aeruginosa, K. pneumonia, S. epidermidis, P. mirabilis, and Streptococcus group D, fungi A.fumigatus (MIC 250 ug/ml) and C.albicans (MIC 1000 ug/ml). Bacteriocidal. Also active against E. coli KCTC 1682 (MI
Evidence 10 Activity

Activity

MIC
Antifungal
1000 µg/mL

Target

C.albicans

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

idermidis, P. mirabilis, and Streptococcus group D, fungi A.fumigatus (MIC 250 ug/ml) and C.albicans (MIC 1000 ug/ml). Bacteriocidal. Also active against E. coli KCTC 1682 (MIC 32 ug/ml), S. typhimurium KCTC
Evidence 11 Activity

Activity

MIC
Antifungal
32 µg/mL

Target

Escherichia coli KCTC 1682

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

gatus (MIC 250 ug/ml) and C.albicans (MIC 1000 ug/ml). Bacteriocidal. Also active against E. coli KCTC 1682 (MIC 32 ug/ml), S. typhimurium KCTC 1926 (MIC 32 ug/ml), B. subtilis KCTC 3068 (MIC 8 ug/ml), and S. aur
Evidence 12 Activity

Activity

MIC
Antifungal
32 µg/mL

Target

S. typhimurium KCTC 1926

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

ns (MIC 1000 ug/ml). Bacteriocidal. Also active against E. coli KCTC 1682 (MIC 32 ug/ml), S. typhimurium KCTC 1926 (MIC 32 ug/ml), B. subtilis KCTC 3068 (MIC 8 ug/ml), and S. aureus KCTC 1621 or 2 strains MRSA (MIC 16-6
Evidence 13 Activity

Activity

MIC
Antifungal
8 µg/mL

Target

B. subtilis KCTC 3068

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

active against E. coli KCTC 1682 (MIC 32 ug/ml), S. typhimurium KCTC 1926 (MIC 32 ug/ml), B. subtilis KCTC 3068 (MIC 8 ug/ml), and S. aureus KCTC 1621 or 2 strains MRSA (MIC 16-64 ug/ml), 2 strains vancomycin-resist
Evidence 14 Activity

Activity

MIC
Antifungal
16-64 µg/mL

Target

Staphylococcus aureus KCTC 1621 or MRSA

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

ug/ml), S. typhimurium KCTC 1926 (MIC 32 ug/ml), B. subtilis KCTC 3068 (MIC 8 ug/ml), and S. aureus KCTC 1621 or 2 strains MRSA (MIC 16-64 ug/ml), 2 strains vancomycin-resistant E. faecium (MIC 32 ug/ml) anti-VRE. Nonstandard assays in
Evidence 15 Activity

Activity

MIC
Antifungal
32 µg/mL

Target

E. faecium

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

d S. aureus KCTC 1621 or 2 strains MRSA (MIC 16-64 ug/ml), 2 strains vancomycin-resistant E. faecium (MIC 32 ug/ml) anti-VRE. Nonstandard assays in 50% LB ( Yang et al., 2006 .
Evidence 16 Activity

Activity

MIC
Antiparasitic
250 µg/mL

Target

A.fumigatus

Source & Reference

DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets.
aeruginosa, K. pneumonia, S. epidermidis, P. mirabilis, and Streptococcus group D, fungi A.fumigatus (MIC 250 ug/ml) and C.albicans (MIC 1000 ug/ml). Bacteriocidal. Also active against E. coli KCTC 1682 (MI
Evidence 17 Activity

Activity

MIC
Antiparasitic
1000 µg/mL

Target

C.albicans

Source & Reference

DRAMP

Other

idermidis, P. mirabilis, and Streptococcus group D, fungi A.fumigatus (MIC 250 ug/ml) and C.albicans (MIC 1000 ug/ml). Bacteriocidal. Also active against E. coli KCTC 1682 (MIC 32 ug/ml), S. typhimurium KCTC
Evidence 18 Activity

Activity

MIC
Antiparasitic
32 µg/mL

Target

Escherichia coli KCTC 1682

Source & Reference

DRAMP

Other

gatus (MIC 250 ug/ml) and C.albicans (MIC 1000 ug/ml). Bacteriocidal. Also active against E. coli KCTC 1682 (MIC 32 ug/ml), S. typhimurium KCTC 1926 (MIC 32 ug/ml), B. subtilis KCTC 3068 (MIC 8 ug/ml), and S. aur
Evidence 19 Activity

Activity

MIC
Antiparasitic
32 µg/mL

Target

S. typhimurium KCTC 1926

Source & Reference

DRAMP

Other

ns (MIC 1000 ug/ml). Bacteriocidal. Also active against E. coli KCTC 1682 (MIC 32 ug/ml), S. typhimurium KCTC 1926 (MIC 32 ug/ml), B. subtilis KCTC 3068 (MIC 8 ug/ml), and S. aureus KCTC 1621 or 2 strains MRSA (MIC 16-6
Evidence 20 Activity

Activity

MIC
Antiparasitic
8 µg/mL

Target

B. subtilis KCTC 3068

Source & Reference

DRAMP

Other

active against E. coli KCTC 1682 (MIC 32 ug/ml), S. typhimurium KCTC 1926 (MIC 32 ug/ml), B. subtilis KCTC 3068 (MIC 8 ug/ml), and S. aureus KCTC 1621 or 2 strains MRSA (MIC 16-64 ug/ml), 2 strains vancomycin-resist
Evidence 21 Activity

Activity

MIC
Antiparasitic
16-64 µg/mL

Target

Staphylococcus aureus KCTC 1621 or MRSA

Source & Reference

DRAMP

Other

ug/ml), S. typhimurium KCTC 1926 (MIC 32 ug/ml), B. subtilis KCTC 3068 (MIC 8 ug/ml), and S. aureus KCTC 1621 or 2 strains MRSA (MIC 16-64 ug/ml), 2 strains vancomycin-resistant E. faecium (MIC 32 ug/ml) anti-VRE. Nonstandard assays in
Evidence 22 Activity

Activity

MIC
Antiparasitic
32 µg/mL

Target

E. faecium

Source & Reference

DRAMP

Other

d S. aureus KCTC 1621 or 2 strains MRSA (MIC 16-64 ug/ml), 2 strains vancomycin-resistant E. faecium (MIC 32 ug/ml) anti-VRE. Nonstandard assays in 50% LB ( Yang et al., 2006 .
Evidence 23 Activity

Activity

37% Hemolysis
Toxicity
100 µg/mL
Hemolytic Cytotoxic
37% Hemolysis | 100 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Evidence 24 Activity

Activity

50% Hemolysis
Toxicity
380 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 380 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structure-function analysis of tritrpticin analogs: potential relationships between antimicrobial activities, model membrane interactions, and their micelle-bound NMR structures. | Biophys J | 2006
Evidence 25 Activity

Activity

IC50
Toxicity
145 µg/mL
Cytotoxic
IC50 | 145 | µg/mL | target cell: Mouse fibroblasts NIH 3T3

Target

Mouse fibroblasts NIH 3T3

Source & Reference

NA
DBAASP
Effect of dimerization of a beta-turn antimicrobial peptide, PST13-RK, on antimicrobial activity and mammalian cell toxicity. | Biotechnol Lett | 2009
Evidence 26 Activity

Activity

40% Hemolysis
Toxicity
190 µM
Hemolytic Cytotoxic
40% Hemolysis | 190 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A Comparison of Activity, Toxicity, and Conformation of Tritrpticin and Two TOAC-labeled Analogues. Effects on the Mechanism of Action. | Biochim Biophys Acta | 2019
Evidence 27 Activity

Activity

IC50
Toxicity
40.6 µM
Cytotoxic
IC50 | 40.6 | µM | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
Selective anticancer activity of synthetic peptides derived from the host defence peptide tritrpticin. | Biochim Biophys Acta | 2020
Evidence 28 Activity

Activity

50% Hemolysis
Toxicity
>120 µM
Hemolytic Cytotoxic
50% Hemolysis | >120 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Cyclic Tritrpticin Analogs with Distinct Biological Activities. | Probiotics Antimicrob Proteins | 2011
Evidence 29 Activity

Activity

50% Hemolysis
Toxicity
190 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 190 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structure-function analysis of tritrpticin analogs: potential relationships between antimicrobial activities, model membrane interactions, and their micelle-bound NMR structures. | Biophys J | 2006
Evidence 30 Activity

Activity

50% Hemolysis
Toxicity
30 µM
Hemolytic Cytotoxic
50% Hemolysis | 30 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Evidence 31 Activity

Activity

50% Hemolysis
Toxicity
62.5 µM
Hemolytic Cytotoxic
50% Hemolysis | 62.5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of perfectly symmetric Trp-rich peptides with potent and broad-spectrum antimicrobial activities. | Int J Antimicrob Agents | 2006
Evidence 32 Activity

Activity

4.55% Hemolysis
Toxicity
294.3 µg/mL
Hemolytic Cytotoxic
4.55% Hemolysis | 294.3 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Characterization of cell selectivity, physiological stability and endotoxin neutralization capabilities of ?-helix-based peptide amphiphiles. | Biomaterials | 2015
Evidence 33 Activity

Activity

IC50
Toxicity
18.4 µM
Cytotoxic
IC50 | 18.4 | µM | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
Selective anticancer activity of synthetic peptides derived from the host defence peptide tritrpticin. | Biochim Biophys Acta | 2020
Evidence 34 Activity

Activity

50% Hemolysis
Toxicity
23.8 µM
Hemolytic Cytotoxic
50% Hemolysis | 23.8 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of perfectly symmetric Trp-rich peptides with potent and broad-spectrum antimicrobial activities. | Int J Antimicrob Agents | 2006
Evidence 35 Hemolysis

Source & Reference

APD_complete APD_hemolytic HemoPI PD_Hemolysis
APD_complete APD_hemolytic PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation.